soupoftheday
2 years ago
We will continue to characterize the most promising candidate molecules for measures of efficacy, safety and pharmaceutical considerations, and expect to have our most promising candidate molecule available to begin partnering conversations
by year end, with additional follow-on indications and a second target, currently in the early stages of development, available for additional licensing or partnering opportunities in 2023."
https://finance.yahoo.com/news/htg-molecular-diagnostics-reports-third-210500124.htm